ID

13996

Descripción

Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01489722

Link

https://clinicaltrials.gov/show/NCT01489722

Palabras clave

  1. 21/3/16 21/3/16 -
Subido en

21 de marzo de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Acute Myeloid Leukemia NCT01489722

Eligibility Acute Myeloid Leukemia NCT01489722

Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
males or females at least 18 years of age
Descripción

Age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
Patients with relapsed or refractory acute myelogenous leukemia (aml) or aml secondary to myelodysplastic syndromes, myeloproliferative neoplasm, or chronic myelogenous leukemia
Descripción

Acute myelogenous leukemia in relapse

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2367456
Eastern oncology cooperative group (ecog) performance status 0-2 and considered likely to complete at least 4 weeks of therapy
Descripción

ECOG performance status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
With the exception of alopecia, any unresolved toxicities from prior therapy greater than ctcae grade 1 at the time of starting study treatment.
Descripción

Mild Adverse Event

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1513302
As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or active infection including hepatitis b, hepatitis c and hiv.
Descripción

Systemic disease

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0442893
UMLS CUI [2]
C2711110
UMLS CUI [3]
C0741554
Active heart disease including myocardial infarction within the last 3 months, symptomatic coronary artery disease, clinically significant arrhythmias not controlled by medication or uncontrolled congestive heart failure
Descripción

Heart Disease

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0018799
Prior allogeneic transplant requiring immunosuppressive therapy (patients with prior allogeneic transplants who remain clinically stable for ≥ 2 weeks or more off immunosuppressive therapy, are eligible)
Descripción

Therapeutic immunosuppression

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021079
White blood cell count ≥ 100,000/mm3 (100x10*9/l)
Descripción

Total white blood count

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1271681
type 1 diabetes or uncontrolled type ii diabetes
Descripción

DM 1

Tipo de datos

boolean

hba1c ≥8% or fasting blood glucose >160 mg/dl (>8.9 mmol/l)
Descripción

Hba1c

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0019018
Baseline fasting total cholesterol >300 mg/dl (>7.75 mmol/l)
Descripción

Total cholesterol

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0543421

Similar models

Eligibility Acute Myeloid Leukemia NCT01489722

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
males or females at least 18 years of age
boolean
C0001779 (UMLS CUI [1])
Acute myelogenous leukemia in relapse
Item
Patients with relapsed or refractory acute myelogenous leukemia (aml) or aml secondary to myelodysplastic syndromes, myeloproliferative neoplasm, or chronic myelogenous leukemia
boolean
C2367456 (UMLS CUI [1])
ECOG performance status
Item
Eastern oncology cooperative group (ecog) performance status 0-2 and considered likely to complete at least 4 weeks of therapy
boolean
C1520224 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Mild Adverse Event
Item
With the exception of alopecia, any unresolved toxicities from prior therapy greater than ctcae grade 1 at the time of starting study treatment.
boolean
C1513302 (UMLS CUI [1])
Systemic disease
Item
As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or active infection including hepatitis b, hepatitis c and hiv.
boolean
C0442893 (UMLS CUI [1])
C2711110 (UMLS CUI [2])
C0741554 (UMLS CUI [3])
Heart Disease
Item
Active heart disease including myocardial infarction within the last 3 months, symptomatic coronary artery disease, clinically significant arrhythmias not controlled by medication or uncontrolled congestive heart failure
boolean
C0018799 (UMLS CUI [1])
Therapeutic immunosuppression
Item
Prior allogeneic transplant requiring immunosuppressive therapy (patients with prior allogeneic transplants who remain clinically stable for ≥ 2 weeks or more off immunosuppressive therapy, are eligible)
boolean
C0021079 (UMLS CUI [1])
Total white blood count
Item
White blood cell count ≥ 100,000/mm3 (100x10*9/l)
boolean
C1271681 (UMLS CUI [1])
DM 1
Item
type 1 diabetes or uncontrolled type ii diabetes
boolean
Hba1c
Item
hba1c ≥8% or fasting blood glucose >160 mg/dl (>8.9 mmol/l)
boolean
C0019018 (UMLS CUI [1])
Total cholesterol
Item
Baseline fasting total cholesterol >300 mg/dl (>7.75 mmol/l)
boolean
C0543421 (UMLS CUI [1])

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial